window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-108383172-1');
Skip to content
Novigenix Logo
  • About us
    • Our Story
    • Team
    • Advisors
    • Compliance
    • Commitment to ESG
  • LITOSeek™
    • LITOSeek Platform
    • Translational Medicine
  • Solutions
    • Prevention through early detection of cancer
    • Precision medicine
    • Innovative drug target discovery
  • Partnerships
  • News
  • Contact
  • About us
    • Our Story
    • Team
    • Advisors
    • Compliance
    • Commitment to ESG
  • LITOSeek™
    • LITOSeek Platform
    • Translational Medicine
  • Solutions
    • Prevention through early detection of cancer
    • Precision medicine
    • Innovative drug target discovery
  • Partnerships
  • News
  • Contact
technology-evolution-graph-4066px-03Sebastien2019-08-21T12:44:37+02:00

Novigenix

Novigenix is a pioneering TechBio delivering liquid biopsy multi-omic solutions powered by the LITOSeek™ AI-RNA analytics platform to accelerate early cancer detection and development of effective therapies for better patient outcomes.

Contact us

  • Route de la Corniche 3
    Phenyl Building
    CH-1066 Epalinges
    Switzerland
  • partnerships@novigenix.com

Follow us on LinkedIn

Recent posts

  • Novigenix awarded EUR 1.8M in the groundbreaking BRECISE IHI Consortium to industrialize AI-powered liquid biopsy for prediction of immunotherapy response
  • New study reveals novel multi-omics approach with unprecedented treatment response prediction in metastatic urothelial cancer
  • Breakthrough study reveals blood transcriptomic alternations for early detection of colorectal cancer

Newsletter

COPYRIGHT 2024 NOVIGENIX SA | ALL RIGHTS RESERVED | PRIVACY POLICY | POWERED BY AGENCE-ACP |
Page load link
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Learn more Ok

Privacy Notice

Go to Top

Notifications